Categories |
|
Therapeutic Areas: Latest reports |
|
Biotechnology
Cancer
Consumer
Customer Relationship Management
Drug Delivery
eHealthcare Pharma
eHealthcare Physician
Generics
Healthcare
Medical Devices
OTC Pharmaceuticals
Pharmaceuticals
Pharmacoeconomics
Therapeutic Areas:
- Cardiovascular
- Central Nervous System
- Immune Disorders and Inflammation
- Infectious Diseases
- Oncology
- Women'sHealth
|
|
|
- Pipeline Insight: HIV - Enter the New Generation Inhibitors 26-April-2004
In-depth appraisal of HIV antiretroviral pipeline covering Phase I to Phase III candidates in NRTI, NNRTI, PI and EI classes, including critical appraisal of product profile, clinical trial design and global forecasts to 2012
------------------------------------------------------------------------------------------------------------------------- |
- Stakeholder Opinions: Malignant Melanoma - High Hurdles, High Rewards, Are Vaccines Only Skin Deep? 16-April-2004
Key issues in the malignant melanoma market, including current diagnosis and treatment patterns, insight into pipeline drugs, and stakeholder opinions.
------------------------------------------------------------------------------------------------------------------------- |
- Adult ADHD - Strattera Grows Up 18-Mar-2004
Provides an overview of adult ADHD and identifies the current market leaders and forecasts sales in this emerging market. Primary contenders for entrance in to the market and lifecycle management of current products are evaluated.
------------------------------------------------------------------------------------------------------------------------- |
- Stakeholder Insight: Fibromyalgia - Substantial Growth Opportunity for SNRI Antidepressants
19-Mar-2004
Fibromyalgia is a relatively common chronic pain syndrome, affecting around 2% of the population. This little understood market suffers from high unmet need both at the level of drug research and current clinical practice. Several leading industry players, including Pfizer, Eli Lilly, and Wyeth, have expressed an interest in this niche thus highlighting the commercial opportunity it offers.
------------------------------------------------------------------------------------------------------------------------- |
- Commercial Perspectives: Cytotoxics - Third-Generation Cytotoxics To Offset Taxol’s Generic Woes - 9-Mar-2004
Key issues in the cytotoxic market including profiles of key cytotoxic drugs, their sales forecasts to 2011, and lifecycle and portfolio management of cytotoxic products.
------------------------------------------------------------------------------------------------------------------------- |
| |
| |
| |
